Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates and breast carcinoma

A Lipton1

  • 1Department of Medicine, Hershey Medical Center, Pennsylvania 17033, USA.

Cancer
|November 15, 1997
PubMed
Summary

Pamidronate significantly reduces skeletal complications in breast cancer patients with bone metastases. This bisphosphonate therapy decreases fractures, vertebral collapse, and the need for radiation or surgery, improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RANKL enhances the effect of an antagonist of inhibitor of apoptosis proteins (cIAPs) in RANK-positive breast cancer cells.

Journal of bone oncology·2016
Same author

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.

European journal of cancer (Oxford, England : 1990)·2015
Same author

Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.

Journal of gastrointestinal cancer·2014
Same author

Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.

Clinical oncology (Royal College of Radiologists (Great Britain))·2012
Same author

Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

Cancer treatment reviews·2012
Same author

Transforming growth-factor-alpha and factor-beta(1) levels in plasma and effusions from patients with cancer or hematologic malignancies.

International journal of oncology·2011

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metastasis Research

Background:

  • Breast carcinoma frequently metastasizes to the skeleton, leading to lytic bone destruction.
  • Osteoclastic overactivity drives bone resorption in skeletal metastases.
  • Bisphosphonates are a class of drugs that inhibit osteoclastic activity and bone resorption.

Purpose of the Study:

  • To evaluate the efficacy of pamidronate, a second-generation aminobisphosphonate, in reducing skeletal complications in patients with Stage IV breast carcinoma and lytic bone lesions.
  • To assess the impact of pamidronate on fracture incidence, vertebral collapse, spinal cord compression, and the need for bone-related interventions.

Main Methods:

  • Two large Phase III studies were pooled for analysis, including patients receiving cytotoxic chemotherapy or endocrine therapy.
  • Patients received either pamidronate (90 mg monthly infusion for 2 years) or a placebo.
  • Outcomes measured included time to first skeletal complication, time to first fracture, proportion of patients with fractures, proportion receiving bone radiation, and skeletal morbidity rate.

Main Results:

  • Pamidronate significantly increased the median time to the first skeletal complication (12.7 vs. 7.0 months) and the time to the first fracture (25.2 vs. 12.8 months).
  • The proportion of patients experiencing fractures (40% vs. 52%), bone radiation (29% vs. 43%), and any skeletal event (51% vs. 64%) was significantly lower in the pamidronate group.
  • Pamidronate also reduced the skeletal morbidity rate and decreased pain and analgesic use.

Conclusions:

  • The addition of pamidronate to standard chemotherapy or endocrine therapy significantly reduces skeletal complications in breast carcinoma patients with osteolytic bone metastases.
  • Pamidronate therapy leads to a sustained reduction in skeletal morbidity, including fractures and the need for interventions.
  • While not impacting overall survival, pamidronate improves the quality of life by reducing skeletal-related events and associated pain.

Related Experiment Videos